The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection

P and T

Volumn 36, Issue 6, 2011, Pages 346-364

  Schafer, Jason J ^a   Ravi, Saranyu ^b   Rowland, Evelyn V ^b   Shenoda, Germin ^b   Leon, Nicholas ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATORVASTATIN; CARBAMAZEPINE; CLARITHROMYCIN; DARUNAVIR; DIAZEPAM; DIHYDROPYRIDINE; DILTIAZEM; EDURANT; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FLUCONAZOLE; ITRACONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LORAZEPAM; MARAVIROC; MEVINOLIN; MIDAZOLAM; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PRAVASTATIN; RIFABUTIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR; SIMVASTATIN; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE; ZIDOVUDINE;

ANXIETY; AREA UNDER THE CURVE; BEDTIME DOSAGE; CD4 LYMPHOCYTE COUNT; CONCENTRATION LOSS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HEADACHE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERSENSITIVITY REACTION; INSOMNIA; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MENTAL INSTABILITY; NAUSEA; NIGHTMARE; PRACTICE GUIDELINE; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VIVID DREAM;

EID: 79960023378     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Sustiva (efavirenz), package insert. Princeton, N.J.: Bristol-Myers Squibb; 2010.
2. Figueroa S, Fernandez M, Garcia L, et al. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. Ther Drug Monit 2010;32:579-585.
3. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300.
4. Poirier JM, Guiard-Schmid JB, Meynard JL, et al. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors. AIDS 2006;20(7): 1087-1089.
5. Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65(4):523-530.
6. Weiner M, Benator D, Peloquin CA, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 2005;41(9):1343-1349.
7. Matteelli A, Regazzi M, Villani P, et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007;5(3):349-353.
8. Ji P, Damle B, Xie J, Unger SE, et al. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol 2008;48(8):948-956.
9. Sulkowski M, Thomas D, Shruti, Mehta S, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatotology 2002; 35:182-189.
10. Jena A, Sachdeva R, Sharma A, Wanchu A. Adverse drug reactions to non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimen: A 24-week prospective study. J Int Assoc Physicians AIDS Care 2009;8:318-322.
11. Pérez-Molina, J. Safety and tolerance of efavirenz in different anti retroviral regimens: Results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002;3(4):279-286.
12. Lochet P, Peyriere H, Lotthe A, et al. Long term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003;4:62-66.
13. Arendt G, de Nocker D, von Giesen HJ, et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6: 147-154.
14. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: Quality of life, psychologic issues, and adherence. J Acquir Immun Defic Syndr 2005;38:560-565.
15. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immun Defic Syndr 2008;48:450-454.
16. Hsu H, Rydzak C, Cotich K. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med 2011;12(2):97-108.
17. Cassetti I, Madruga J, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007;8:164-172.
18. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005;19: 463-471.
19. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regiments including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomized open-label trial, the 2NN study. Lancet 2004;363: 1253-1263.
20. Nelson M, Staszewski S, Morales-Ramirez JO, et al. Successful virologic suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: Post hoc results from study 006. Abstract 3-349. Abstracts of the Tenth European Congress of Clinical Microbiology and Infectious Diseases, 2000, Stockholm.
21. Riddler S, Haubrich R, DiRienzo A, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358: 2095-2106.
22. DeJesus E, Young B, Morales-Ramirez J, et al. Simplification of anti retroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV- 1-infected patients. J Acquir Immune Defic Syndr 2009;51:163-174.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; pp 1-166. Available at: www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 31, 2011.
24. Hirsh MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS society-USA panel. Clin Infect Dis 2003;37:113-128.
25. Hsiou Y, Ding J, Clark AD Jr, et al. The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance. J Mol Biol 2001;309:437-445.
26. Halvas E, Wiegand A, Boltz V, et al. Low-frequency non-nucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010;201:672-680.
27. Viramune (nevirapine), product label. Ridgefield, Conn.: Boehringer Ingelheim; 2010.
28. Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999;27:895-901.
29. Cramer YS, Rosenkranz SL, Hall SD, et al. Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: Results from ACTG 15177. J Acquir Immune Defic Syndr 2010;54:5-7.
30. Leith J, Piliero P, Storfer S, et al. Appropriate use of nevirapine for long-term therapy. J Infect Dis 2005;192:545.
31. th Interscience Conference of Antimicrobial Agents and Chemo - therapy, Sepember 2009, San Francisco.
32. Levin J. Assessment of steady state PK parameters of two extended release (XR) nevirapine (NVP) tablets 400 mg and 300 mg QD compared with immediate release (IR) NVP tablets 200 mg BID in HIV-1 infected patients: The ERVIR study. 12th European AIDS Conference, November 11-14, 2009, Cologne, Germany.
33. Gathe J, Bogner JR, Santiago S, et al. Comparison of 48-week efficacy and safety of 400 mg QD nevirapine extended release formulation (Viramune XR) versus 200 mg BID nevirapine immediate release formulation (Viramune IR) in combination with Truvada in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE). 18th International AIDS Conference, July 18-23, 2010, Vienna.
34. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIVinfected patients. J AIDS 2003;34:S21-S33.
35. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005;19: 463-471.
36. Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatmentlimiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009;23:1689-1699.
37. Wit FW, Kesselring AM, Gras L, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naïve patients: The ATHENA cohort study. Clin Infect Dis 2008;46:933-940.
38. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
39. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010;363:1499-1509.
40. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010;363:1510-1520.
41. Arrivé E, Newell ML, Chaix ML, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: A meta-analysis. Int J Epidemiol. 2007;36:1009-1021.
42. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999;13:479-486.
43. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after singledose administration. J Antimicrob Chemother 2009;63:170-177.
44. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Towards Universal Access. Recommendation for a Public Health Approach. 2010 version, pp 1-116. Available at: www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html. Accessed November 19, 2010.
45. Intellence (etravirine), product label. Raritan, N.J.: Tibotec; 2008.
46. th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago.
47. Scholler-Gyure M, Boffito M, Pozniak AL, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy 2008;28(10):1215-1222.
48. Raoof A, Mannens B, Mamidi R, et al. In vivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers. AAPS J 2006;8(Suppl 2):M1342.
49. Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmaco - kinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011;50(1):25-39.
50. th International Congress on Drug Therapy in HIV Infection, November 12-16, 2006, Glasgow.
51. th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2006, San Francisco.
52. th Conference on Retroviruses and Opportunistic Infections, February 2006, Denver.
53. Madruga JV, Cahn P, Grinztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomized, doubleblind, placebo-controlled trial. Lancet 2007;370:29-38.
54. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomized, doubleblind, placebo-controlled trial. Lancet 2007;370:39-48.
55. Katlama C, Haubrich R, Lalezaric J, et al. Efficacy and safety of etravirine in treatment experienced, HIV-1 patients: Pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23(17):2289-2300.
56. Davis J, Scholler-Gyure M, Kakuda TN, et al. An open randomized two period crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/DRV/r on the steady state pharmacokinetics of oral maraviroc in healthy subjects. Abstract P4.3/02. 11th European AIDS Conference, October 2007, Madrid.
57. Scholler-Gyure M, Kakuda T, Smedt GD, et al. Effects of hepatic impairment on the steady state pharmacokinetics of etravirine 200 mg BID: An open-label, multiple-dose, controlled phase I study in adults. Clin Ther 2010;32(2):328-337.
58. Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmaco - kinetics of etravirine in pregnant HIV-infected women. HIV Med 2011;12(4):257-258.
59. A study to assess the pharmacokinetics (blood levels) of TMC114 (darunavir) taken with TMC114r (ritonavir), and TMC125 (etravirine) in HIV-1 infected pregnant women. Available at: http://clinicaltrials.gov/ct2/show/NCT00855335. Accessed May 23, 2011.
60. th Conference on Retroviruses and Opportunistic Infections, February 6-8, 2008, Boston.
61. Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125- R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47: 2550-2560.
62. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 2005;79:12773-12782.
63. th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston.
64. Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysis. AIDS 2007;21:F1-F10.
65. Rilpivirine (Edurant), prescribing information. Raritan, N.J.: Tibotec Therapeutics, Division of Centocor Ortho Biotech Products, L.P.
66. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: Week 96 results of a phase IIb randomized trial. AIDS 2010;24;55-65.
67. Hoetelmans R, Kestens D, Marien K, et al. Effect of food and multiple-dose pharmacokinetics of TMC 278 as an oral tablet formulation: Healthy volunteers. Abstract TuPe.1B10. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, July 24-27, 2005, Rio de Janeiro.
68. De Bethune M-P, Andries K, Azijn H, et al. TMC278, a new potent NNRTI with an increased barrier to resistance and good pharmacokinetic profile. Poster 556. 12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005, Boston.
69. Verloes R, Van't Klooster G, Baert L, et al. TMC278 long acting: A parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers. Poster TUP0042. XVII International AIDS Conference (AIDS 2008), August 3-8, 2008, Mexico City.
70. FDA declines New Drug Application for rilpivirine/Truvada combination pill. January 28, 2011. Available at: www.hivandhepatitis. com/recent/2011/0128)b.html. Accessed May 10, 2011.
71. Van Heeswijk R, Hoetelmans RMW, Kestens D, et al. The pharmacokinetic (PK) interaction between TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), and oncedaily darunavir/ritonavir (DRV/r) in HIV-negative volunteers. Abstract H-1042. 47th Interscience Conference on Anti microbial Agents and Chemotherapy, September 17-20, 2007, Chicago.
72. Van Heeswijk RP, Hoetelmans RM, Kestens D, et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational nonnucleoside reverse transcriptase inhibitor in healthy, HIV-negative subjects. Abstract TUPE0087. XVI International AIDS Conference; August 13-18, 2006, Toronto.
73. Scholler-Gyure M, Debroye C, Vyncke V, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI). Abstract 45. 7th International Workshop on Clinical Pharmacology of HIV Therapy, April 20-22, 2006, Lisbon.
74. th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, July 22-25, 2007, Sydney.
75. Cohen C, Molina JM, Cahn P. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomized, phase III trials comparing TMC278 versus efavirenz in treatmentnaive, HIV-1-infected patients. Abstract THLBB206. XVIII International AIDS Conference (AIDS 2010), July 18 -23, 2010, Vienna.
76. Azijn H, Tirry I, Vingerhoest J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54(2):718-727.
77. Das K, Bauman JD, Clark AD, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 2008;105:1466-1471.
78. Rimsky L, Eron J, Clotet B, et al. Characterization of the resistance profile of TMC278: 48-week analysis of the phase 3 studies ECHO and THRIVE. Abstract H-1810. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010, Boston.
79. Wakeham K, Parkes-Ratashi R, Watson V, et al. Co-administration of fluconazole increases nevirapine concentrations in HIV- infected Ugandans. J Antimicrob Chemother 2010;65:316-319.
80. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007;63:451-456.
81. Lamson M, Robinson P, Lamson M, et al. The pharmacokinetic interaction of nevirapine and ketoconazole. Abstract 12218. Abstracts of the 12th World AIDS Conference, 1988, Geneva.
82. Robinson P, Gigliotti M, Lamson M, et al. Effects of the reverse transcriptase inhibitor, nevirapine, on the steady-state pharmacokinetics of clarithromycin in HIV-positive patients. Abstract 374. 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 3, 1999, Chicago.
83. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001;28:450-453.
84. de Maat MM, Hoetelmans RM, Matht RA, et al. Drug interaction between St. John's wort and nevirapine. AIDS 2001;15:420-421.
85. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J AIDS 2002;29:471-477.
86. Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agent Chemother 2004;48:4148-4153.
87. Liedtke MD, Rathbu CR. Warfarin-antiretroviral interactions. Ann Pharmacother 2009;43:322-328.
88. Barrett S, Joshi S, Chai M, et al. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002; 40(11):507-519.
89. Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, et al. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV- infected patients. Eur J Clin Pharmacol 2007;63(5):479-483.
90. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immun Defic Syndr 2009;51(4):437-444.
91. Kuper JI, D'Aprile M. Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000;39(3):203-214.
92. Creus T, Cortés L, Rodríguez E, et al. Interactions that can compromise response to antiretroviral therapy. The AIDS Study Group (Grupo de Estudio del Sida [GeSIDA]). Enferm Infecc Microbiol Clin 2006;24(Suppl 2):19-28.
93. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008;13(2):123-132.
94. Gerber J, Rosenkranz S, Fichtenbaum C, et al. AIDS Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS Clinical Trials Group 5108 Study. J Acquir Immun Defic Syndr 2005;39(3):307-312.
95. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002;36(10):1598-1613.